Monitoring Agency Report for the quarter ended on 31st March, 2026
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings Limited, as Monitoring Agency, has submitted its report on utilization of IPO proceeds for Akums Drugs and Pharmaceuticals Limited for Q4 FY26. The IPO raised Rs 6,800 million (net proceeds Rs 6,421.80 million) in July-August 2024. Of this, Rs 6,373.70 million (99.25%) has been utilized as at March 31, 2026, with Rs 48.10 million remaining unutilized. Key allocations include full repayment of company and subsidiary debt (Rs 3,870 million combined), working capital funding (Rs 550 million), and partial deployment for acquisitions (Rs 278.70 million of Rs 301.80 million proposed). A minor reallocation of Rs 48.10 million from issue expenses was approved by the Board in February 2026, redirecting funds to GCP and acquisition objectives. There is a slight delay in the acquisitions object, originally planned for FY25 but now expected to be completed in FY26.
The IPO proceeds are being deployed largely as intended with no material deviations. The Rs 48.10 million unutilized balance and minor delay in acquisition spending are not concerning given the significant debt reduction achieved. Shareholders can note that the company has successfully reduced its debt burden using IPO funds.